Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate

European Journal of Cancer

Volumn 46, Issue 10, 2010, Pages 1841-1847

  Israels, Trijn ^a,b   Damen, Carola W N ^c   Cole, Michael ^d   van Geloven, Nan ^e   Boddy, Alan V ^d   Caron, Huib N ^b   Beijnen, Jos H ^c   Molyneux, Elizabeth M ^a   Veal, Gareth J ^d  

^a UNIVERSITY OF MALAWI   (Malawi)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Clearance; Malnutrition; Pharmacokinetics; Vincristine; Wilms

Indexed keywords

CREATININE; ELECTROLYTE; LIVER ENZYME; PROTEIN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ANTHROPOMETRIC PARAMETERS; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG PROTEIN BINDING; ECHOGRAPHY; ELECTROLYTE BLOOD LEVEL; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALAWI; MALE; MALNUTRITION; MASS SPECTROMETRY; NEPHROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL STATUS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR VOLUME; UNITED KINGDOM; ADOLESCENT; COMPLICATION; KIDNEY NEOPLASMS; METABOLIC CLEARANCE RATE; METABOLISM; WILMS TUMOR;

ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CHILD; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALAWI; MALE; MALNUTRITION; METABOLIC CLEARANCE RATE; VINCRISTINE; WILMS TUMOR;

EID: 77953288141     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.03.002     Document Type: Article

References (23)

1. Hadley G.P., and Shaik A.S. The morbidity and outcome of surgery in children with large pre-treated Wilms' tumour: size matters. Pediatr Surg Int 22 (2006) 409-412
2. Madani A., Zafad S., Harif M., et al. Treatment of Wilms tumor according to SIOP 9 protocol in Casablanca, Morocco. Pediatr Blood Cancer 46 (2006) 472-475
3. Israels T., Chirambo C., Caron H.N., and Molyneux E.M. Nutritional status at admission of children with cancer in Malawi. Pediatr Blood Cancer 51 (2008) 626-628
4. Israels T., and Molyneux E.M. Preoperative chemotherapy for patient with Wilms tumour in Malawi is feasible and efficacious. Pediatr Blood Cancer 53 4 (2009) 584-589
5. Gidding C.E., Meeuwsen-de Boer G.J., Koopmans P., et al. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol 44 (1999) 203-209
6. Groninger E., Meeuwsen-de Boer T., Koopmans P., et al. Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG). Eur J Cancer 41 (2005) 98-103
7. Frost B.M., Lonnerholm G., Koopmans P., et al. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr 92 (2003) 551-557
8. De Graaf S.S., Bloemhof H., Vendrig D.E., and Uges D.R. Vincristine disposition in children with acute lymphoblastic leukemia. Med Pediatr Oncol 24 (1995) 235-240
9. Groninger E., Meeuwsen-de Boer T., Koopmans P., et al. Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr Res 52 (2002) 113-118
10. Sethi V.S., and Kimball J.C. Pharmacokinetics of vincristine sulfate in children. Cancer Chemother Pharmacol 6 (1981) 111-115
11. Estlin E.J., and Veal G.J. Clinical and cellular pharmacology in relation to solid tumours of childhood. Cancer Treat Rev 29 (2003) 253-273
12. Moore A., and Pinkerton R. Vincristine: can its therapeutic index be enhanced?. Pediatr Blood Cancer 53 7 (2009) 1180-1187
13. Baker S.D., Grochow L.B., and Donehower R.C. Should anticancer drug doses be adjusted in the obese patient?. J Natl Cancer Inst 87 (1995) 333-334
14. Murry D.J., Riva L., and Poplack D.G. Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl 11 (1998) 48-51
15. Donigian D.W., and Owellen R.J. Interaction of vinblastine, vincristine and colchicine with serum proteins. Biochem Pharmacol 22 (1973) 2113-2119
16. Breiman R.S., Beck J.W., Korobkin M., et al. Volume determinations using computed tomography. Am J Roentgenol 138 (1982) 329-333
17. Hamill P.V., Drizd T.A., Johnson C.L., et al. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr 32 (1979) 607-629
18. Damen C.W., Israels T., Caron H.N., et al. Validated assay for the simultaneous quantification of total vincristine and actinomycin-D concentrations in human EDTA plasma and of vincristine concentrations in human plasma ultrafiltrate by high-performance liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 23 (2009) 763-774
19. Tournade M.F., Com-Nougue C., de Kraker J., et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J Clin Oncol 19 (2001) 488-500
20. Desai Z.R., van den Berg H.W., Bridges J.M., and Shanks R.G. Can severe neurotoxicity beprevented?. Cancer Chemother Pharmacol 8 (1982) 211-214
21. Sethi V.S., Jackson Jr. D.V., and White D.R. Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 41 (1981) 3551-3555
22. Nelson R.L. The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine and vinblastine in human patients with cancer. Med Pediatr Oncol 10 (1982) 115-127
23. Xie H.G., Wood A.J., Kim R.B., et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5 (2004) 243-272